iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Get Free Report) was the target of a significant increase in short interest in August. As of August 14th, there was short interest totaling 33,524 shares, an increase of 114.6% from the July 30th total of 15,622 shares. Currently, 0.6% of the company’s stock are sold short. Based on an average daily volume of 50,553 shares, the short-interest ratio is currently 0.7 days.
Institutional Investors Weigh In On iShares Genomics Immunology and Healthcare ETF
An institutional investor recently raised its position in iShares Genomics Immunology and Healthcare ETF stock. Ameriprise Financial Inc. grew its holdings in iShares Genomics Immunology and Healthcare ETF (NYSEARCA:IDNA – Free Report) by 8.4% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 71,473 shares of the company’s stock after acquiring an additional 5,540 shares during the quarter. Ameriprise Financial Inc. owned 1.42% of iShares Genomics Immunology and Healthcare ETF worth $1,688,000 at the end of the most recent reporting period.
iShares Genomics Immunology and Healthcare ETF Trading Down 3.2%
Shares of IDNA traded down $1.31 during midday trading on Friday, hitting $39.29. 74,451 shares of the company’s stock traded hands, compared to its average volume of 48,792. iShares Genomics Immunology and Healthcare ETF has a 1 year low of $22.12 and a 1 year high of $41.49. The firm’s fifty day moving average is $34.53 and its 200-day moving average is $31.32. The stock has a market capitalization of $231.81 million, a price-to-earnings ratio of 14.76 and a beta of 0.93.
About iShares Genomics Immunology and Healthcare ETF
The iShares Genomics Immunology and Healthcare ETF (IDNA) is an exchange-traded fund that mostly invests in stocks based on a particular theme. The fund tracks a market-cap-selected and -weighted index of global stocks involved in genomics, immunology, and bioengineering. IDNA was launched on Jun 11, 2019 and is managed by BlackRock.
Further Reading
- Five stocks we like better than iShares Genomics Immunology and Healthcare ETF
- Strike a Balance Between Growth and Stability With These 3 Names Ready to Rally
- Rubrik’s AI Security Bet Could Power the Next Leg Higher
- Apple’s Foldable iPhone Could Be a Catalyst, But Not a Cure-All
- Snowflake Is Up Nearly 50% in 2026—What Are Short Sellers Betting Against?
Receive News & Ratings for iShares Genomics Immunology and Healthcare ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iShares Genomics Immunology and Healthcare ETF and related companies with MarketBeat.com's FREE daily email newsletter.
